Mineralys (NASDAQ: MLYS) CMO Form 4 10b5-1 stock sale filing details

Rhea-AI Filing Summary

Mineralys Therapeutics Chief Medical Officer Rodman David Malcom reported option exercises and share sales in company stock. On January 13, 2026, he exercised stock options for 3,542 shares at $10.20 per share and 4,167 shares at $14.25 per share, receiving the same number of common shares. That day he sold 7,709 shares at $32.75 per share, followed by a sale of 11,367 shares at a weighted-average price of $32.6071 on January 14, 2026.

The filing states these transactions were made under a Rule 10b5-1 trading plan adopted on October 6, 2025. After the reported trades, Malcom beneficially owned 50,437 shares of common stock, plus stock options for 131,042 shares and 104,167 shares that vest over time according to their grant terms.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodman David Malcom

(Last) (First) (Middle)

150 N. RADNOR CHESTER RD.

SUITE F200

(Street)

RADNOR PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/13/2026		M(1)		3,542	A	$10.2	65,346	D
Common Stock	01/13/2026		M(1)		4,167	A	$14.25	69,513	D
Common Stock	01/13/2026		S(1)		7,709	D	$32.75	61,804	D
Common Stock	01/14/2026		S(1)		11,367	D	$32.6071(2)	50,437	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$10.2	01/13/2026		M(1)			3,542	(3)	02/13/2035	Common Stock	3,542	$0	131,042	D
Stock Option	$14.25	01/13/2026		M(1)			4,167	(4)	02/13/2034	Common Stock	4,167	$0	104,167	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.99 to $32.91. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

3. The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant.

4. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Remarks:

	/s/ Adam Levy, Attorney-in-fact	01/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider trading Mineralys Therapeutics (MLYS) stock in this Form 4?

The Form 4 reports transactions by Rodman David Malcom, who serves as Chief Medical Officer of Mineralys Therapeutics, Inc.

What Mineralys (MLYS) stock transactions did the CMO report on January 13, 2026?

On January 13, 2026, the CMO exercised options for 3,542 shares at $10.20 and 4,167 shares at $14.25, then sold 7,709 shares of common stock at $32.75 per share.

What Mineralys (MLYS) stock sale was reported on January 14, 2026?

On January 14, 2026, the CMO sold 11,367 shares of Mineralys common stock at a weighted-average price of $32.6071, executed in multiple trades within a disclosed price range.

Was the Mineralys (MLYS) insider trading done under a Rule 10b5-1 plan?

Yes. The filing explains that the transactions were effected under a Rule 10b5-1 trading plan that was adopted on October 6, 2025.

How many Mineralys (MLYS) shares does the CMO own after these transactions?

Following the reported trades, the CMO beneficially owned 50,437 shares of common stock, as well as stock options for 131,042 shares and 104,167 shares, all held directly.

What are the vesting terms of the Mineralys (MLYS) stock options in this Form 4?

One stock option vests in monthly installments over four years, with 1/48th of the shares vesting each month. Another option vested 25% on the first anniversary of grant, with the remaining shares vesting in 36 substantially equal monthly installments.